drugset
drugset / Trial / NCT06184633

DUTCH Weight Control in Atrial Fibrillation Study

NCT06184633 ↗

Phase 4 Recruiting 280 enrolled Rijnstate Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

Quantify the effect of an innovative weight loss management on rhythm control.

Timeline

Start
2024-07-21
Primary completion
2026-05-01
Completion
2027-05-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Semaglutide Peptide 2.4 mg Subcutaneous

Indications

atrial fibrillation obesity disorder